Search

Delgocitinib

Delgocitinib is a pan-Janus kinase (JAK) inhibitor. After the first global approval in Japan,[A264693] delgocitinib was also approved by the European Commission on September 23, 2024. … [A264703] On July 23, 2025, delgocitinib was also granted approval by the FDA.[L53508]

Eprosartan

By preventing the binding of angiotensin II to AT1, vascular smooth muscle relaxes and vasodilation occurs. By inhibiting norepinephrine production, blood pressure is further reduced. … Eprosartan is an angiotensin II receptor antagonist used to treat hypertension. It performs 2 actions on the renin angiotensin system.

Ethosuximide

An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.

Ragweed pollen extract

Ragweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.

DL-Methylephedrine

Methylephedrine is not legally available in the United States, but has been identified in cases of drug abuse [L2836].

Zinc chloride

Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes. Zinc chloride was granted FDA approval before 26 June 1986.

Ethinylestradiol

Ethinylestradiol was first synthesized in 1938 by Hans Herloff Inhoffen and Walter Hohlweg at Schering.[A191107] It was developed in an effort to create an estrogen with greater oral bioavailability. … [A191107] These properties were achieved by the substitution of an ethinyl group at carbon 17 of [estradiol].[A191107] Ethinylestradiol soon replaced [mestranol] in contraceptive pills.

Sodium phosphate, dibasic

Insulin beef

Insulin beef has been discontinued in the US and Canada since 2017.[L10827]

Human cytomegalovirus immune globulin

CMV infection can lead to a high fever and severe organ-specific damage with significant morbidity and mortality rates. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].